Synopsys Inc (SNPS) 59.14 $SNPS Synopsys Replenishes

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 11:21 PM

Synopsys Inc (SNPS) 59.14 $SNPS

Synopsys Replenishes Repurchase Authorization to $500 Million
PR Newswire - Thu Sep 01, 3:05PM CDT
Synopsys, Inc. (Nasdaq: SNPS) today announced that its Board of Directors has replenished its existing stock repurchase authorization back to $500 million.
SNPS: 59.14 (-0.15)

Synopsys Shares Up 36.4% Since SmarTrend's Buy Recommendation (SNPS)
Comtex SmarTrend(R) - Wed Aug 31, 12:35AM CDT
SmarTrend identified an Uptrend for Synopsys (NASDAQ:SNPS) on February 17th, 2016 at $43.32. In approximately 7 months, Synopsys has returned 36.40% as of today's recent price of $59.08.
SNPS: 59.14 (-0.15)

Synopsys Announces Results of Robert S. Hilbert Memorial Optical Design Competition
PR Newswire - Thu Aug 25, 8:05AM CDT
Synopsys, Inc. (Nasdaq: SNPS) today announced that students from the University of Rochester, University of Saskatchewan, University of Southern California and the University of Arizona received awards for their entries in the 2016 Robert S. Hilbert Memorial Optical Design Competition. The annual competition is open to students in North America working toward a bachelor's, master's or doctorate degree who utilize Synopsys' CODE V® or LightTools® software to perform optical design and engineering research. The awards are granted to students who have submitted papers that demonstrate optical design excellence.
SNPS: 59.14 (-0.15)

Synopsys (SNPS) Touches 52-Week High: Should You Hold?
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 9:30AM CDT
Shares of Synopsys Inc. (SNPS) hit a new 52-week high of $59.04 on Aug 23, 2016, eventually closing at $58.93.
MENT: 24.29 (+0.28), FB: 126.17 (+0.05), CDNS: 25.51 (+0.07), SNPS: 59.14 (-0.15)

Gridbee Achieves First-Pass Silicon Success with Synopsys' DesignWare ARC Processor
PR Newswire - Wed Aug 24, 8:05AM CDT
Highlights:
SNPS: 59.14 (-0.15)

Shares of SNPS Up 36.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 23, 1:04PM CDT
SmarTrend identified an Uptrend for Synopsys (NASDAQ:SNPS) on February 17th, 2016 at $43.32. In approximately 6 months, Synopsys has returned 36.05% as of today's recent price of $58.93.
SNPS: 59.14 (-0.15)

Ride Nasdaq's 8-Week Rally with These 4 Tech Stocks
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 7:34AM CDT
With Nasdaq logging its longest weekly winning streak in six years, it is time to invest in attractive tech stocks.
AMZN: 770.62 (+1.46), FB: 126.17 (+0.05), STX: 33.71 (-0.03), GOOGL: 791.40 (+1.55), SNPS: 59.14 (-0.15), NTAP: 34.93 (+0.34), MSFT: 57.59 (+0.13), CSCO: 31.58 (+0.14), NVDA: 63.15 (+1.81)

Look for Shares of Synopsys to Potentially Pullback after Yesterday's 4.53% Rise
Comtex SmarTrend(R) - Thu Aug 18, 1:15PM CDT
Synopsys (NASDAQ:SNPS) traded in a range yesterday that spanned from a low of $57.15 to a high of $58.47. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $56.29 on volume of 812,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNPS: 59.14 (-0.15)

Synopsys (SNPS) Q3 Earnings & Revenues Top; View Strong
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:48AM CDT
Synopsys Inc. (SNPS) posted better-than-expected third quarter of fiscal 2016 results.
MENT: 24.29 (+0.28), FB: 126.17 (+0.05), CDNS: 25.51 (+0.07), SNPS: 59.14 (-0.15)

Symantec (SYMC) Touches 52-Week High: Should You Hold?
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 8:17AM CDT
Shares of Symantec Corporation (SYMC) hit a new 52-week high of $22.97 on Aug 15, eventually closing at $22.88.
SNPS: 59.14 (-0.15), INTC: 36.02 (+0.13), MSFT: 57.59 (+0.13), SYMC: 24.15 (+0.02)

29.4% Return Seen to Date on SmarTrend Synopsys Call (SNPS)
Comtex SmarTrend(R) - Tue Aug 16, 12:57AM CDT
SmarTrend identified an Uptrend for Synopsys (NASDAQ:SNPS) on February 17th, 2016 at $43.32. In approximately 6 months, Synopsys has returned 29.42% as of today's recent price of $56.06.
SNPS: 59.14 (-0.15)

Synopsys (SNPS) Q3 Earnings: Can the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 2:22PM CDT
Synopsys Inc. (SNPS) is set to report third-quarter fiscal 2016 results on Aug 17.
ADI: 63.06 (+0.50), SNPS: 59.14 (-0.15), BABA: 97.42 (+0.23), SJM: 140.66 (-1.13)

Zacks.com featured highlights: Laboratory Corp. of America Holdings, Synopsys, Intel, VMware and Euronet Worldwide
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:30AM CDT
Zacks.com featured highlights: Laboratory Corp. of America Holdings, Synopsys, Intel, VMware and Euronet Worldwide
VMW: 73.78 (+0.45), LH: 136.13 (-0.80), EEFT: 77.91 (+0.30), SNPS: 59.14 (-0.15), INTC: 36.02 (+0.13)

Synopsys Shares Up 27.3% Since SmarTrend's Buy Recommendation (SNPS)
Comtex SmarTrend(R) - Mon Aug 08, 1:40PM CDT
SmarTrend identified an Uptrend for Synopsys (NASDAQ:SNPS) on February 17th, 2016 at $43.32. In approximately 6 months, Synopsys has returned 27.28% as of today's recent price of $55.13.
SNPS: 59.14 (-0.15)

5 Stocks with Incredible Sales Growth to Buy Now
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:56AM CDT
A careful selection of stocks considering certain factors should help investors to not only build wealth but beat the market as well - Laboratory Corp. of America Holdings (LH), Synopsys Inc. (SNPS), Intel Corporation (INTC) in focus.
VMW: 73.78 (+0.45), LH: 136.13 (-0.80), EEFT: 77.91 (+0.30), SNPS: 59.14 (-0.15), INTC: 36.02 (+0.13)

Synopsys Announces Earnings Release Date for Third Quarter Fiscal Year 2016
PR Newswire - Wed Aug 03, 3:05PM CDT
Synopsys, Inc. (Nasdaq: SNPS) today announced it will report results for the third quarter fiscal year 2016 on Wednesday, Aug. 17, 2016, after the market close.
SNPS: 59.14 (-0.15)

Seagate (STX) Beats Q4 Earnings & Revenues but Down Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 8:59AM CDT
Seagate Technology plc (STX) reported better-than-expected results for the fourth quarter of fiscal 2016 wherein both the top and bottom line surpassed the respective Zacks Consensus Estimate.
STX: 33.71 (-0.03), SNPS: 59.14 (-0.15), WDC: 46.32 (-0.35), ADBE: 102.90 (+0.59)

SYNOPSYS (SNPS) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Synopsys Inc. For Potential Breach of Fiduciary Duty
BusinessWire - Mon Aug 01, 7:09AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Synopsys Inc. (NASDAQGS: SNPS) ("Synopsys" or the "Company"

.
SNPS: 59.14 (-0.15)

Synopsys Up 24.9% Since SmarTrend Uptrend Call (SNPS)
Comtex SmarTrend(R) - Fri Jul 29, 1:44PM CDT
SmarTrend identified an Uptrend for Synopsys (NASDAQ:SNPS) on February 17th, 2016 at $43.32. In approximately 5 months, Synopsys has returned 24.92% as of today's recent price of $54.11.
SNPS: 59.14 (-0.15)

Synopsys' New Model for Infineon's Next Generation TriCore Architecture Accelerates Early Automotive Software Development and Test
PR Newswire - Thu Jul 28, 8:05AM CDT
Highlights:
SNPS: 59.14 (-0.15)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

EFICYENT Ventures to Connect at Singapore FinTech Fest

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Retirement Dreams Dashed: 61% Withdraw Early

By Olivia Taylor Updated Nov 14, 2026 Category News Views 309

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...